Skip to content

Evaluation of the effect of airway clearance with an oscillatory positive expiratory pressure device (Aerobika) in patients with nontuberculous mycobacterial pulmonary disease: a randomized controlled trial.

Evaluation of the effect of airway clearance with an oscillatory positive expiratory pressure device (Aerobika) in patients with nontuberculous mycobacterial pulmonary disease: a randomized controlled trial. - Evaluation of the effect of airway clearance with an oscillatory positive expiratory pressure device in patients with nontuberculous mycobacterial pulmonary disease: a randomized controlled trial.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000056274
Enrollment
60
Registered
2024-11-26
Start date
2024-11-26
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nontuberculous mycobacterial pulmonary disease

Interventions

In the intervention group, airway clearance with an oscillatory positive expiratory pressure device will be performed for a minimum of two sessions per day for eight weeks, with each session lasting a

Sponsors

Fukujuji Hospital,Japan Anti-Tuberculosis Association
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria were patients with nontuberculous mycobacterial pulmonary disease admitted for treatment who met all of the following criteria 1. bronchiectasis on chest CT within 2 years prior to study entry 2. cough and sputum symptoms 3. able to use OPEP and have cognitive function to answer the questionnaire

Exclusion criteria

Exclusion criteria: Exclusion criteria are as follows 1. those who used physiotherapy or devices such as OPEP at present or within the past year 2. Patients who were hospitalized urgently due to exacerbation, etc. 3. those with unstable medical conditions 4. those with any acute disease requiring treatment 4. who require treatment for any acute illness Patients with medical conditions or symptoms that are contraindications to the use of OPEP 6. patients with chronic obstructive pulmonary disease, interstitial lung disease, or bronchial asthma 7. patients with malignant tumors 8. current smokers 9. Persons with dementia or psychiatric diseases that the principal investigator or project leader determines to be difficult to evaluate 10. any other person who is judged to be ineligible by the Principal Investigator or a research associate

Design outcomes

Primary

MeasureTime frame
Main outcome is quality of life at 4 and 8 weeks after the start of the intervention

Countries

Japan

Contacts

Public ContactKazuki Ono

Fukujuji Hospital, Japan Anti-Tuberculosis Association Respiratory Care and Rehabilitation Center

k.ono2964@gmail.com0424914111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026